Increased Inflammatory Markers Are Associated with Obesity and Not with Target Organ Damage in Newly Diagnosed Untreated Essential Hypertensive Patients

REFERENCES

• Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311(8):501–505.
   Google Scholar
• Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342(12):836–843.
   Google Scholar
• Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101(15):1767–1772.
   Google Scholar
• Van Der Meer IM, De Maat MP, Hak AE, . C-reactive protein predicts progression of atherosclerosis measured at various sites in the arterial tree: the Rotterdam Study. Stroke 2002; 33(12):2750–2755.
   Google Scholar
• Sung KC, Suh JY, Kim BS, . High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens 2003; 16(6):429–433.
   Google Scholar
• Bautista LE, López-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens 2001; 19(5):857–861.
   Google Scholar
• Stefanadi E, Tousoulis D, Androulakis ES, . Inflammatory markers in essential hypertension: potential clinical implications. Curr Vasc Pharmacol 2010; 8(4):509–516.
   Google Scholar
• Vindis A, Schiffrin EL. Vascular inflammation: a role in vascular disease in hypertension. Curr Opin Nephrol Hypertens 2003; 12(2):181–187.
   Google Scholar
• Savoia C, Schiffrin EL. Inflammation in hypertension. Curr Opin Nephrol Hypertens 2006; 15(2):152–158.
   Google Scholar
• Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323(1):22–27.
   Google Scholar
• Puddu P, Puddu GM, Zaca F, Muscari A. Endothelial dysfunction in hypertension. Acta Cardiol 2000; 55(4):221–232.
   Google Scholar
• Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322(22):1561–1566.
   Google Scholar
• Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114(5):345–352.
   Google Scholar
• Weir MR. Microalbuminuria and cardiovascular disease. Clin J Am Soc Nephrol 2007; 2(3):581–590.
   Google Scholar
• Gerstein HC, Mann JF, Yi Q, . Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286(4):421–426.
   Google Scholar
• Thoenes M, Bramlage P, Khan BV, Schieffer B, Kirch W, Weir MR. Albuminuria: pathophysiology, epidemiology and clinical relevance of an emerging marker for cardiovascular disease. Future Cardiol 2007; 3(5):519–524.
   Google Scholar
• Perticone F, Maio R, Ceravolo R, Cosco C, Cloro C, Mattioli PL. Relationship between left ventricular mass and endothelium-dependent vasodilation in never-treated hypertensive patients. Circulation 1999; 99(15):1991–1996.
   Google Scholar
• Krieger DR, Landsberg L. Mechanisms in obesity-related hypertension: role of insulin and catecholamines. Am J Hypertens 1988; 1(1):84–90.
   Google Scholar
• Bogers RP, Bemelmans WJ, Hoogenveen RT, Boshuizen HC, Woodward M, Knekt P. Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300 000 persons. Arch Intern Med 2007; 167(16):1720–1728.
   Google Scholar
• Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA 1999; 282(16):1523–1529.
   Google Scholar
• Scaglione R, Argano C, Di Chiara T, Licata G. Obesity and cardiovascular risk: the new public health problem of worldwide proportions. Expert Rev Cardiovasc Ther 2004; 2(2):203–212.
   Google Scholar
• Després JP, Lemieux I, Bergeron J, Pibarot P, Mathieu P, Larose E. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 2008; 28(6):1039–1049.
   Google Scholar
• Mathieu P, Lemieux I, Després JP. Obesity, inflammation, and cardiovascular risk. Clin Pharmacol Ther 2010; 87(4):407–416.
   Google Scholar
• Mehta S, Farmer JA. Obesity and inflammation: a new look at an old problem. Curr Atheroscler Rep 2007; 9(2):134–138.
   Google Scholar
• Koch R, Sharma AM. Obesity and cardiovascular hemodynamic function. Curr Hypertens Rep 1999; 1(2):127–130.
   Google Scholar
• Bruzzi I, Benigni A, Remuzzi G. Role of increased glomerular protein traffic in the progression of renal failure. Kidney Int Suppl 1997; 62:29–31.
   Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289(19):2560–2572.
   Google Scholar
• Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58(6):1072–1083.
   Google Scholar
• Devereux RB, Alonso DR, Lutas EM, . Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57(6):450–458.
   Google Scholar
• Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103(13):1813–1818.
   Google Scholar
• Pedrinelli R, Dell’Omo G, Di Bello V, . Low-grade inflammation and microalbuminuria in hypertension. Arterioscler Thromb Vasc Biol 2004; 24(12):2414–2419.
   Google Scholar
• Leoncini G, Sacchi G, Ravera M, . Microalbuminuria is an integrated marker of subclinical organ damage in primary hypertension. J Hum Hypertens 2002; 16(6):399–404.
   Google Scholar
• Wachtell K, Palmieri V, Olsen MH, . Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy. Am Heart J 2002; 143(2):319–326.
   Google Scholar
• Dell’omo G, Giorgi D, Di Bello V, Mariani M, Pedrinelli R. Blood pressure independent association of microalbuminuria and left ventricular hypertrophy in hypertensive men. J Intern Med 2003; 254(1):76–84.
   Google Scholar
• Roselló-Lletí E, Rivera M, Martínez-Dolz L, . Inflammatory activation and left ventricular mass in essential hypertension. Am J Hypertens 2009; 22(4):444–450.
   Google Scholar
• Perticone F, Maio R, Tripepi G, Sciacqua A, Mallamaci F, Zoccali C. Microalbuminuria endothelial dysfunction and inflammation in primary hypertension. J Nephrol 2007; 20(Suppl. 12):S56–S62.
   Google Scholar
• Palmieri V, Tracy RP, Roman MJ, . Relation of left ventricular hypertrophy to inflammation and albuminuria in adults with type 2 diabetes: the strong heart study. Diabetes Care 2003; 26(10):2764–2769.
   Google Scholar
• Lieb W, Mayer B, Stritzke J, . Association of low-grade urinary albumin excretion with left ventricular hypertrophy in the general population. Nephrol Dial Transplant 2006; 21(10):2780–2787.
   Google Scholar
• Kramer H, Jacobs DR Jr, Bild D, . Urine albumin excretion and subclinical cardiovascular disease. The multi-ethnic study of atherosclerosis. Hypertension 2005; 46(1):38–43.
   Google Scholar
• Brattström L, Wilcken DE. Homocysteine and cardiovascular disease: cause or effect? Am J Clin Nutr 2000; 72(2):315–323.
   Google Scholar